Puerperal Lactation Suppression and Prolactin

Gezelle, H. de; Dhont, Marc; Thiéry, Michel; Parewyck, W

doi:10.3109/00016347909154069

Cited by 14 publications

(7 citation statements)

References 16 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Androgens such as testosterone inhibit lactation, and in the era before dopamine agonists, testosterone alone, or in combination with estrogens, was used to inhibit lactation 20,21 . In our pilot study we found that the pre‐androgen DHEAS showed a weak negative correlation with breastfeeding in women who have PCOS 4 .…”

Section: Discussionmentioning

confidence: 72%

Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow‐up study of a randomised controlled trial on metformin versus placebo

Vanky

Nordskar

Leithe

et al. 2012

BJOG

View full text Add to dashboard Cite

Objective To study the significance of breast size increment in pregnancy, and the impact of metformin during pregnancy on breastfeeding in women with polycystic ovary syndrome (PCOS).Design A follow-up study of a randomised controlled trial (the PregMet study).Setting Eleven secondary care centres.Population Women with PCOS during pregnancy and postpartum.Methods Women with PCOS were randomised to treatment with metformin or placebo from the first trimester to delivery. Questionnaires were sent to 240 participants 1 year postpartum: 186 responded.Main outcome measures Pre-pregnancy and late-pregnancy brassiere size and breastfeeding patterns were registered, and androgen levels were measured in the mothers.Results No difference in breast size increment and breastfeeding were found between the placebo and metformin groups.Breast size increment correlated positively with the duration of both exclusive and partial breastfeeding, whereas body mass index (BMI) correlated negatively with the duration of partial breastfeeding. Dehydroepiandrostenedione-sulphate (DHEAS), testosterone and free testosterone index (FTI) in pregnancy did not correlate with breast size increment or duration of breastfeeding. Women with no change in breast size were more obese, had higher blood pressure, serum triglycerides and fasting insulin levels, and had a shorter duration of breastfeeding compared with those with breast size increment.Conclusions Metformin and androgens had no impact on breastfeeding. Women with PCOS who had no breast size increment in pregnancy seem to be more metabolically disturbed and less able to breastfeed.Keywords Androgens, breast size increment, breastfeeding, metformin, polycystic ovary syndrome, pregnancy.Please cite this paper as: Vanky E, Nordskar J, Leithe H, Hjorth-Hansen A, Martinussen M, Carlsen S. Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow-up study of a randomised controlled trial on metformin versus placebo.

show abstract

Section: Discussionmentioning

confidence: 72%

Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow‐up study of a randomised controlled trial on metformin versus placebo

Vanky

Nordskar

Leithe

et al. 2012

BJOG

View full text Add to dashboard Cite

show abstract

“…It seems that one physiological role of testosterone is to limit the estrogenic stimulation of the breast (21, 22). Before dopamine agonists became available for lactation inhibition, testosterone was used for this purpose (10–12). Further, we have recently reported that breastfeeding rates were lower among pregnant women with PCOS and associated negatively with DHEAS levels in the third trimester (14).…”

Section: Discussionmentioning

confidence: 99%

“…However, the effects of androgens have been sparsely focused. Before dopamine agonists were introduced, androgens were used to suppress lactation (10–12). Pregnant women with polycystic ovary syndrome (PCOS) have elevated androgen levels (13).…”

Section: Introductionmentioning

confidence: 99%

Mid‐pregnancy androgen levels are negatively associated with breastfeeding

Carlsen¹,

Jacobsen²,

Vanky

2010

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…The clinical effectiveness of bromocrip tine (Parlodel®), a dopamine agonist, in both preventing and suppressing postpartum milk secretion is well established [4][5][6][7][8][9][10]. More re cently it has been reported that a serotonin antagonist, metergoline (Liserdol®), is able to lower plasma PRL and suppress lactation in puerperal women [11,12].…”

Section: Discussionmentioning

confidence: 99%

Puerperal Lactation Inhibition with a Novel 8α-Aminoergoline (CU 32-085)

Poulsen¹,

Rasmussen²,

Petersen³

et al. 1984

Gynecol Obstet Invest

View full text Add to dashboard Cite

The clinical efficacy of CU 32-085, a novel ergoline derivative, in puerperal lactation inhibition was investigated in 41 healthy postpartum women and compared with serum concentrations of prolaction (PRL) and CU 32-085. The women received 0.5 mg CU 32-085 twice daily for 14 days. In 40 women (i.e. 97%) treatment with CU 32-085 successfully inhibited lactation; slight to moderate breast activity appearing during the first few days receded spontaneously. 1 woman experienced full milk let-down on day 5 of treatment. No rebound lactational phenomena were recorded. 5 h after the initial dose, mean serum PRL concentrations decreased by 82% (from 169 to 30 ng/ml), and PRL values remained at that level during the course of treatment. The mean serum concentrations of CU 32-085 showed an inverse pattern compared to PRL. CU 32-085 was well tolerated, with transient slight to moderate dizziness, headache and nausea reported by 12 women (29%) following the initial dose. These disappeared after an average of 3 h. Routine safety chemistries remained within the normal range, and no statistically significant differences between the treatment group and the control group (25 normal nursing postpartum women) were encountered. It is concluded that CU 32-085, a potent dopamine agonist, is an effective and well-tolerated treatment in the indication of postpartum lactation inhibition.

show abstract

Puerperal Lactation Suppression and Prolactin

Cited by 14 publications

References 16 publications

Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow‐up study of a randomised controlled trial on metformin versus placebo

Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow‐up study of a randomised controlled trial on metformin versus placebo

Mid‐pregnancy androgen levels are negatively associated with breastfeeding

Puerperal Lactation Inhibition with a Novel 8α-Aminoergoline (CU 32-085)

Contact Info

Product

Resources

About